Evidence map›Paper›PMID 24688782›Full record

ReviewJournal of thoracic disease2014

New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Sarah A Mattonen, Kitty Huang, Aaron D Ward, Suresh Senan, David A Palma

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. SBRT for lung oligometastases: Who is the perfect candidate?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sarah A Mattonen1 Department of Medical Biophysics, 2 Department of Oncology, The University of Western Ontario, London, ON, Canada ; 3 Division of Radiation Oncology, London Regional Cancer Program, London, ON, Canada ; 4 Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Kitty Huang1 Department of Medical Biophysics, 2 Department of Oncology, The University of Western Ontario, London, ON, Canada ; 3 Division of Radiation Oncology, London Regional Cancer Program, London, ON, Canada ; 4 Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Aaron D Ward1 Department of Medical Biophysics, 2 Department of Oncology, The University of Western Ontario, London, ON, Canada ; 3 Division of Radiation Oncology, London Regional Cancer Program, London, ON, Canada ; 4 Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Suresh Senan1 Department of Medical Biophysics, 2 Department of Oncology, The University of Western Ontario, London, ON, Canada ; 3 Division of Radiation Oncology, London Regional Cancer Program, London, ON, Canada ; 4 Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
David A Palma1 Department of Medical Biophysics, 2 Department of Oncology, The University of Western Ontario, London, ON, Canada ; 3 Division of Radiation Oncology, London Regional Cancer Program, London, ON, Canada ; 4 Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Amsterdam UMC Location Vrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypofractionated radiotherapy (HFRT) is an effective and increasingly-used treatment for early stage non-small cell lung cancer (NSCLC). Stereotactic ablative radiotherapy (SABR) is a form of HFRT and delivers biologically effective doses (BEDs) in excess of 100 Gy10 in 3-8 fractions. Excellent long-term outcomes have been reported; however, response assessment following SABR is complicated as radiation induced lung injury can appear similar to a recurring tumor on CT. Current approaches to scoring treatment responses include Response Evaluation Criteria in Solid Tumors (RECIST) and positron emission tomography (PET), both of which appear to have a limited role in detecting recurrences following SABR. Novel approaches to assess response are required, but new techniques should be easily standardized across centers, cost effective, with sensitivity and specificity that improves on current CT and PET approaches. This review examines potential novel approaches, focusing on the emerging field of quantitative image feature analysis, to distinguish recurrence from fibrosis after SABR.

Indexed as

hypofractionated radiotherapy (HFRT)image feature analysisLung cancerpositron emission tomography (PET)stereotactic radiotherapy

Identifiers

PMID24688782
PMCPMC3968559
OpenAlexW2097687932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.